Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations
Splice-modulating antisense oligonucleotides (ASOs) offer treatment options for rare neurological diseases, including those with very rare mutations, where patient-specific, individualized ASOs have to be developed. Inspired by the development of milasen, the 1 Mutation 1 Medicine (1M1M) and Dutch C...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 20, 2023
|
| In: |
RNA
Year: 2023, Jahrgang: 29, Heft: 4, Pages: 446-454 |
| ISSN: | 1469-9001 |
| DOI: | 10.1261/rna.079540.122 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1261/rna.079540.122 Verlag, lizenzpflichtig, Volltext: http://rnajournal.cshlp.org/content/29/4/446 
|
| Verfasserangaben: | Annemieke Aartsma-Rus, Willeke van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, and Holm Graessner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1843596768 | ||
| 003 | DE-627 | ||
| 005 | 20230706211846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230426s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1261/rna.079540.122 |2 doi | |
| 035 | |a (DE-627)1843596768 | ||
| 035 | |a (DE-599)KXP1843596768 | ||
| 035 | |a (OCoLC)1389530467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Aartsma-Rus, Annemieke |e VerfasserIn |0 (DE-588)1159167427 |0 (DE-627)1021159050 |0 (DE-576)504744232 |4 aut | |
| 245 | 1 | 0 | |a Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe |b development, regulation, and implementation considerations |c Annemieke Aartsma-Rus, Willeke van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, and Holm Graessner |
| 264 | 1 | |c January 20, 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.04.2023 | ||
| 520 | |a Splice-modulating antisense oligonucleotides (ASOs) offer treatment options for rare neurological diseases, including those with very rare mutations, where patient-specific, individualized ASOs have to be developed. Inspired by the development of milasen, the 1 Mutation 1 Medicine (1M1M) and Dutch Center for RNA Therapeutics (DCRT) aim to develop patient-specific ASOs and treat eligible patients within Europe and the Netherlands, respectively. Treatment will be provided under a named patient setting. Our initiatives benefited from regulatory advice from the European Medicines Agency (EMA) with regard to preclinical proof-of-concept studies, safety studies, compounding and measuring benefit and safety in treated patients. We here outline the most important considerations from these interactions and how we implemented this advice into our plan to develop and treat eligible patients within Europe. | ||
| 650 | 4 | |a antisense oligonucleotides | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a N = 1 | |
| 650 | 4 | |a regulators | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Roon-Mom, Willeke van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lauffer, Marlen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siezen, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duijndam, Britt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roo, Tineke Coenen-de |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schüle-Freyer, Rebecca |d 1975- |e VerfasserIn |0 (DE-588)137544472 |0 (DE-627)695848283 |0 (DE-576)30411118X |4 aut | |
| 700 | 1 | |a Synofzik, Matthis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Graessner, Holm |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RNA |d Cold Spring Harbor, NY : Laboratory Press, 1995 |g 29(2023), 4 vom: Jan., Seite 446-454 |h Online-Ressource |w (DE-627)269758844 |w (DE-600)1475737-0 |w (DE-576)25220901X |x 1469-9001 |7 nnas |a Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe development, regulation, and implementation considerations |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:4 |g month:01 |g pages:446-454 |g extent:9 |a Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe development, regulation, and implementation considerations |
| 856 | 4 | 0 | |u https://doi.org/10.1261/rna.079540.122 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://rnajournal.cshlp.org/content/29/4/446 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230426 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 137544472 |a Schüle-Freyer, Rebecca |m 137544472:Schüle-Freyer, Rebecca |d 910000 |d 911100 |e 910000PS137544472 |e 911100PS137544472 |k 0/910000/ |k 1/910000/911100/ |p 7 | ||
| 999 | |a KXP-PPN1843596768 |e 4314667001 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Annemieke Aartsma-Rus, Willeke van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, and Holm Graessner"]},"note":["Gesehen am 26.04.2023"],"person":[{"given":"Annemieke","display":"Aartsma-Rus, Annemieke","role":"aut","family":"Aartsma-Rus"},{"display":"Roon-Mom, Willeke van","given":"Willeke van","family":"Roon-Mom","role":"aut"},{"family":"Lauffer","role":"aut","display":"Lauffer, Marlen","given":"Marlen"},{"role":"aut","family":"Siezen","given":"Christine","display":"Siezen, Christine"},{"given":"Britt","display":"Duijndam, Britt","family":"Duijndam","role":"aut"},{"given":"Tineke Coenen-de","display":"Roo, Tineke Coenen-de","family":"Roo","role":"aut"},{"display":"Schüle-Freyer, Rebecca","given":"Rebecca","role":"aut","family":"Schüle-Freyer"},{"given":"Matthis","display":"Synofzik, Matthis","family":"Synofzik","role":"aut"},{"family":"Graessner","role":"aut","given":"Holm","display":"Graessner, Holm"}],"recId":"1843596768","id":{"eki":["1843596768"],"doi":["10.1261/rna.079540.122"]},"physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe","title":"Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe","subtitle":"development, regulation, and implementation considerations"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"January 20, 2023"}],"relHost":[{"origin":[{"dateIssuedDisp":"1995-","publisher":"Laboratory Press ; HighWire Press","publisherPlace":"Cold Spring Harbor, NY ; Stanford, Calif.","dateIssuedKey":"1995"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["269758844"],"issn":["1469-9001"],"zdb":["1475737-0"]},"title":[{"title_sort":"RNA","title":"RNA"}],"recId":"269758844","name":{"displayForm":["publ. on behalf of the RNA Society"]},"disp":"Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe development, regulation, and implementation considerationsRNA","type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"RNA Society","role":"isb"}],"pubHistory":["1.1995 -"],"note":["Gesehen am 12.09.2018"],"part":{"year":"2023","volume":"29","pages":"446-454","extent":"9","issue":"4","text":"29(2023), 4 vom: Jan., Seite 446-454"},"language":["eng"]}]} | ||
| SRT | |a AARTSMARUSDEVELOPMEN2020 | ||